Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities.While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).If you have $1,000 to spare (don't dip into money earmarked for important things or a rainy day!), here's why it might be worth investing in these drugmakers.Continue reading
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities.
While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).
If you have $1,000 to spare (don't dip into money earmarked for important things or a rainy day!), here's why it might be worth investing in these drugmakers.
